Trials / Completed
CompletedNCT01720264
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
A Multicenter Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Sherif S. Farag · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this trial is to assess the efficacy and safety of sitagliptin in enhancing engraftment following umbilical cord blood transplantation (recovery of blood counts after transplant).
Detailed description
Umbilical cord blood (UCB) is more commonly used for transplantation in children but is being used in adults more often. However, because adults are larger than children, the relatively smaller stem cell dose in UCB is major limitation for transplantation in adults and engraftment can be delayed. This study is trying to find out if the drug sitagliptin can be used to increase and speed up engraftment in adults receiving UCB transplantation.
Conditions
- Acute Myeloid Leukemia
- Acute Lymphoid Leukemia
- Hematopoetic Myelodysplasia
- Leukemia, Myelogenous, Chronic
- Lymphoma, Non-Hodgkin
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sitagliptin | Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3. |
Timeline
- Start date
- 2012-11-02
- Primary completion
- 2016-08-27
- Completion
- 2017-12-15
- First posted
- 2012-11-02
- Last updated
- 2019-01-08
- Results posted
- 2019-01-08
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01720264. Inclusion in this directory is not an endorsement.